Identification
Name(4aS,4bR,10bS,12aS)-12a-methyl-1,3-dioxo-2-(pyridin-3-ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-dodecahydronaphtho[2,1-f]isoquinolin-8-yl sulfamate
Accession NumberDB08418
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 469.553
Monoisotopic: 469.167141679
Chemical FormulaC24H27N3O5S
InChI KeyLSJKARAMQNGZDF-YOEKFXIASA-N
InChI
InChI=1S/C24H27N3O5S/c1-24-9-8-19-18-7-5-17(32-33(25,30)31)11-16(18)4-6-20(19)21(24)12-22(28)27(23(24)29)14-15-3-2-10-26-13-15/h2-3,5,7,10-11,13,19-21H,4,6,8-9,12,14H2,1H3,(H2,25,30,31)/t19-,20-,21+,24+/m1/s1
IUPAC Name
(1R,2S,7S,10S)-7-methyl-4,6-dioxo-5-(pyridin-3-ylmethyl)-5-azatetracyclo[8.8.0.0²,⁷.0¹¹,¹⁶]octadeca-11(16),12,14-trien-14-yl sulfamate
SMILES
[H][C@]12CC[C@]3(C)C(=O)N(CC4=CC=CN=C4)C(=O)C[C@@]3([H])[C@]1([H])CCC1=C2C=CC(OS(N)(=O)=O)=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Carbonic anhydrase 2ProteinunknownNot AvailableHumanP00918 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0287 mg/mLALOGPS
logP2.65ALOGPS
logP2.4ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)10.85ChemAxon
pKa (Strongest Basic)4.81ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area119.66 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity121.2 m3·mol-1ChemAxon
Polarizability49.05 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9794
Caco-2 permeable-0.6225
P-glycoprotein substrateSubstrate0.5489
P-glycoprotein inhibitor INon-inhibitor0.508
P-glycoprotein inhibitor IINon-inhibitor0.7992
Renal organic cation transporterNon-inhibitor0.6765
CYP450 2C9 substrateNon-substrate0.8745
CYP450 2D6 substrateNon-substrate0.7849
CYP450 3A4 substrateSubstrate0.6322
CYP450 1A2 substrateNon-inhibitor0.7506
CYP450 2C9 inhibitorNon-inhibitor0.7402
CYP450 2D6 inhibitorNon-inhibitor0.8541
CYP450 2C19 inhibitorNon-inhibitor0.7292
CYP450 3A4 inhibitorNon-inhibitor0.7296
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7053
Ames testNon AMES toxic0.5589
CarcinogenicityNon-carcinogens0.5741
BiodegradationNot ready biodegradable0.988
Rat acute toxicity2.5850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7208
hERG inhibition (predictor II)Inhibitor0.5054
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene.
KingdomChemical entities
Super ClassOrganic compounds
ClassBenzenoids
Sub ClassPhenanthrenes and derivatives
Direct ParentPhenanthrenes and derivatives
Alternative ParentsIsoquinolones and derivatives / Tetralins / Piperidinediones / Delta lactams / Pyridines and derivatives / N-substituted carboxylic acid imides / Organic sulfuric acids and derivatives / Heteroaromatic compounds / Dicarboximides / Azacyclic compounds
SubstituentsPhenanthrene / Isoquinolone / Tetralin / Piperidinedione / Delta-lactam / Piperidinone / Carboxylic acid imide, n-substituted / Piperidine / Pyridine / Carboxylic acid imide
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on September 15, 2010 15:31 / Updated on June 11, 2017 21:17